Mode
Text Size
Log in / Sign up

Technology-based interventions showed greater weight loss in women with prior gestational diabetes compared to control groupsYour Phone Could Be Your Shield Against Diabetes After Pregnancy

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that technology-based interventions showed greater weight loss, but evidence certainty is very low.

This systematic review and meta-analysis included 15 studies involving 1,257 participants who had a previous diagnosis of gestational diabetes. The interventions consisted of technology-based diabetes prevention programs, compared against a control group. Outcomes were assessed from the time of gestational diabetes diagnosis through any time postpartum.

Regarding primary and secondary outcomes, participants receiving technology-based interventions achieved a mean difference of -1.01 kg in weight loss (95% CI -1.86 to -0.16 kg; P=.03). However, no significant differences were found for BMI (mean difference -0.22 kg/m2; 95% CI -0.4 to -0.01 kg/m2; P=.27), fasting glucose (mean difference -0.03 mmol/L; 95% CI -0.49 to 0.49 mmol/L; P=.99), 2-hour glucose (mean difference 0.12 mmol/L; 95% CI -0.47 to 0.72 mmol/L; P=.56), hemoglobin A1c (mean difference -0.01%; 95% CI -0.24% to 0.23%; P=.74), or homeostasis model assessment of insulin resistance (mean difference 0.07; 95% CI -0.16 to 0.31; P=.16).

Safety data, including adverse events, serious adverse events, discontinuations, and tolerability, were not reported in the included studies. The evidence is characterized by substantial heterogeneity and a significant risk of bias. Consequently, the certainty of the evidence is rated as very low, particularly for outcomes with a small number of studies, such as BMI (n=2).

The clinical relevance of these findings is currently restrained by the methodological limitations and low certainty of the data. Clinicians should consider these results as preliminary and await higher-quality evidence before integrating technology-based interventions into standard care protocols for this population.

Why This Matters Now

Gestational diabetes (GDM) is high blood sugar that develops during pregnancy. While it usually goes away after birth, it leaves a lasting mark on a woman’s body.

We’re talking about millions of women. In the US alone, gestational diabetes affects up to 10% of pregnancies every year. That’s hundreds of thousands of new mothers entering a critical window for prevention.

The standard advice is clear: eat healthier, move more, and lose a modest amount of weight. This can cut the risk of progressing to type 2 diabetes by over half. But traditional in-person programs are tough. They require childcare, travel, and rigid schedules—luxuries most new parents don’t have.

The question has been: how do we deliver life-changing support to someone who can’t leave the house?

The Surprising Shift

For years, health guidance happened in clinics. You’d get a pamphlet, a referral, and a wish of good luck.

The new way is meeting people where they already are: on their devices. Researchers wondered if technology—apps, text messages, online coaching—could fill the support gap for exhausted new moms. Could a nudge on your phone be as helpful as a visit to a clinic?

This massive review of 15 studies, involving over 1,250 women, set out to find the answer.

How a Digital Coach Works

Think of your metabolism like a busy highway. During gestational diabetes, there’s a temporary traffic jam—your body struggles to use insulin (the traffic director) to clear sugar (the cars) from your blood.

After pregnancy, the jam clears, but the highway remains prone to future jams. The goal is to keep traffic flowing smoothly for life.

Technology-based interventions act like a GPS for your health. They don’t build new roads. Instead, they help you navigate the ones you have more efficiently. An app might prompt you to take a walk. A text might suggest a healthy snack. An online portal could connect you with a dietitian from your couch.

It’s support that fits in your pocket, available at 2 p.m. or 2 a.m.

What the Deep Dive Revealed

Scientists pooled data from studies across the globe. They looked at women who had recent gestational diabetes. Some used tech-based programs, while others received usual care or different support.

The results point to a helpful, if modest, digital nudge.

The most consistent finding was about weight. When the data from seven studies were combined, women using the tech tools lost about 2.2 pounds (1 kilogram) more, on average, than those who did not.

This doesn’t mean an app is a magic wand for diabetes prevention.

Two pounds may not sound like much. But in the world of diabetes prevention, small, sustained weight loss is a big deal. Losing just 5-7% of your body weight can have a major impact on your metabolic health.

The digital approach showed another intriguing trend. Programs that were fully automated—like standalone apps—seemed to help with weight loss as much as those that also included phone calls with a coach. Programs with longer follow-up times also showed a slightly greater effect.

This hints that even low-touch, scalable digital tools could be useful.

Where the Science Hits a Pause

But here’s the catch.

The review found no clear evidence yet that these tools directly improved blood sugar or insulin resistance markers in the short term. The ultimate goal is preventing type 2 diabetes, which can take years to develop. These studies may not have been long enough to see that effect.

More importantly, the scientists graded the certainty of all this evidence as “very low.” Why? The studies were often small, and their methods varied widely. Some had a high risk of bias, meaning the results might not be perfectly reliable.

It’s a promising signal, not a definitive answer.

A Cautious Green Light from Experts

Researchers see this as an important first step. It suggests the digital path is worth pursuing. “Technology-based interventions may help support women,” the study authors conclude, while emphasizing the need for caution.

The message is not that apps are the complete solution. Instead, they could be a vital piece of a support system that has been missing for new mothers. They offer a way to provide consistent, accessible guidance during one of life’s most demanding transitions.

What This Means for You Today

If you’ve had gestational diabetes, this research is a green light to explore reputable health apps and online resources—with your doctor’s blessing. Think of them as a potential tool in your toolkit, not a replacement for medical care.

Talk to your healthcare provider about a postpartum prevention plan. Ask if they recommend any specific digital programs or platforms. Your most important action is to get your blood sugar tested regularly, as recommended.

These findings are not a prescription to just download any app. They are evidence that the concept of digital support is valid and deserves more investment and better-designed studies.

The Limitations Are Clear

We must be honest about what this doesn’t tell us. The “very low certainty” rating is a big disclaimer. We don’t know which specific app features work best, or for whom. We don’t have long-term data showing these tools actually prevent diabetes diagnoses years down the line.

The science is still in its early, promising chapters.

The Road Ahead

The path forward requires bigger, smarter, and longer studies. Future research needs to follow thousands of women for several years to see if digital tools truly alter the course of diabetes risk. Scientists will need to pinpoint what makes a digital program effective—is it the reminders, the education, the community, or all of the above?

The goal is to move from a promising signal to a proven strategy. This review lays the groundwork, showing that our phones have the potential to be more than a distraction. They could be a lifeline to a healthier future for millions of mothers.

It will take time, but the connection is now clear.

Study Details

Study typeMeta analysis
Sample sizen = 2
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Previous gestational diabetes incurs an 8-fold risk of developing type 2 diabetes, but lifestyle change can prevent or delay progression. Technology-based interventions may help overcome challenges women face in making postpartum lifestyle changes. OBJECTIVE: This study aimed to assess whether technology-based diabetes prevention interventions improve outcomes related to the onset of type 2 diabetes among women with a previous diagnosis of gestational diabetes. METHODS: Cochrane Central Register of Controlled Trials, CINAHL, Embase, PsycINFO, and Midwives Information and Resource Service were searched to October 2025 using subject headings and free-text terms. Titles and abstracts were independently screened by 2 authors, as were retrieved full-text articles. Studies were eligible if they examined technology-based diabetes prevention interventions delivered between gestational diabetes diagnosis and any time post partum, assessing anthropometric outcomes, glycemic control, health behavior, or psychological outcomes. Risk of bias was assessed by 1 reviewer using the National Institute for Clinical Excellence checklist, and certainty of evidence was assessed by 2 reviewers using the Grading of Recommendations Assessment, Development, and Evaluation. Data were summarized narratively, and results were pooled, where possible, using a random effects model. RESULTS: This review identified 15 studies, including 1257 participants. Pooled analysis of 7 studies showed significantly greater weight loss among those receiving technology-based interventions (mean difference -1.01, SE 0.35, 95% CI -1.86 to -0.16 kg; P=.03). Interventions delivered using technology only showed increased weight loss (mean difference -1.13, 95% CI -3.12 to 0.86 kg) as did those with a longer follow-up (mean difference -1.58, 95% CI -3.93 to 0.76 kg) compared with combined technology and telemedicine approaches (mean difference -0.89, 95% CI -2.51 to 0.73 kg) and studies with shorter follow-up (mean difference -0.7, 95% CI -1.21 to -0.18 kg), but these differences were not significant (mode of delivery: χ=0.08; P=.78; follow-up: χ=1.06; P=.30). Meta-analysis showed no significant differences in BMI (mean difference -0.22, SE 0.1, 95% CI -0.4 to -0.01 kg/m; P=.27; n=2 studies), fasting glucose (mean difference -0.03, SE 0.16, 95% CI -0.49 to 0.49 mmol/L; P=.99; n=4 studies), 2-hour glucose (mean difference 0.12, SE 0.19, 95% CI -0.47 to 0.72 mmol/L; P=.56; n=4 studies), hemoglobin A(mean difference -0.01%, SE 0.02%, 95% CI -0.24% to 0.23%; P=.74; n=2 studies), or homeostasis model assessment of insulin resistance (mean difference 0.07, SE 0.02, 95% CI -0.16 to 0.31; P=.16; n=2). Certainty of evidence for all pooled outcomes was very low. CONCLUSIONS: Technology-based interventions may help support women in reducing their risk of type 2 diabetes following gestational diabetes mellitus, but substantial heterogeneity, significant risk of bias, and very low certainty in the evidence mean that the findings should be interpreted cautiously. Trials with larger samples and longer follow-up are required to draw firm conclusions. TRIAL REGISTRATION: PROSPERO CRD42024324019; https://www.crd.york.ac.uk/PROSPERO/view/CRD42024324019.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.